Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

<p class="MsoNormal">Featuring an interview with Dr Kevin Kalinsky<span class="normaltextrun">,</span> including the following topics:</p> <ul> <li>Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00) <ul> <li>Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. <em>Oncologist</em> 2025;30(9). <a href= "https://academic.oup.com/oncolo/article/30/9/oyaf225/8211180" target="_blank" rel="noopener">Abstract</a> </li> <li>Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. <em>Oncologist</em> 2025;30(3). <a href="https://academic.oup.com/oncolo/article/30/3/oyaf031/8096319">Abstract</a>  </li> </ul> </li> <li>Clinical Data with Neoadjuvant Datopotamab Deruxtecan from the I-SPY 2.2 Phase II Trial (5:17) <ul> <li>Khoury K et al. Datopotamab–...